Seminal Articles—Prostate Cancer

Based on our expert's review, here are the must-read articles for every oncologist about prostate cancer.

Prevention and Screening

1. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. May 4, 2005;293(17):2095-2101. Free

2. Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. March 26, 2009;360(13):1310-1319. Free

3. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. March 26, 2009;360(13):1320-1328. Free

4. Klotz L, Zhang L, Lam A, et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. January 1, 2010;28(1):126-131.

5. Djulbegovic M, Beyth RJ, Neuberger MM, et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. Br Med J. Published on-line September 14, 2010. Free

Surgery

6. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting. N Engl J Med. May 12, 2005;352:1977-1984. Free

7. Stephenson AJ, Scardino PT, Eastham JA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst. May 17, 2006;98(10):715-717. Free

8. Hu JC, Gu X, Lipsitz SR, et al. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA. October 14, 2009;302(14):1557-1564.

Radiation and Androgen Blockade

9. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. July 31, 1997;337(5):295-300. Free

10. D'Amico AV, Manola J, Loffredo M, et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. August 18, 2004;292(7):821-827. Free

11. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. August 13, 2005;366(9485):572-578. Elsevier

12. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. September 14, 2005;294(10):1233-1239. Free

13. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. November 15, 2006;296(19):2329-2335.

14. Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. January 24, 2009;373(9660):301-308. Elsevier

15. Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. November 2010;11(11):1066-1073. Elsevier

16. Warde P, Mason M, Ding K, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet. Published on-line November 3, 2011. Elsevier, Free athttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3243932/?tool=pubmed 

Androgen Withdrawal

17. Sartor AO, Tangen CM, Hussain MHA, et al. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer. June 1, 2008;112(11):2393-2400. Free

Systemic Therapy

18. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. October 7, 2004;351:1502-1512. Free

19. Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. October 7, 2004;351(15):1513-1520. Free

20. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. July 29, 2010;363(5):411-422. Free

21. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. October 2, 2010;376(9747):1147-1154. Elsevier

22. de Bono JS , Logothetisn CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. May 26, 2011;364(21):1995-2005. Free

23. Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. June 2006;7(6):472-479. Elsevier

Bone

24. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. October 2, 2002;94(19):1458-1468. Free

25. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. March 5, 2011;377(9768):813-822. Elsevier, Free athttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3090685/?tool=pubmed